Pivotal trials and novel combinations have started, but four programmes seem to have been discontinued.
ApexOnco Front Page
Recent articles
Varseta-M efficacy wanes, but more than justifies a pivotal trial.
The company secures funding to push its lead candidate towards US approval.
Readout of the Pivot-006 trial is brought forward by nearly a year.
After Aktis's $318m flotation Eikon is a bigger proposition.
$650m buys the group rights to RemeGen’s RC148.
A pivotal trial will test the KRAS G12D degrader setidegrasib plus chemo in first-line PDAC.
ELVN-001 is made to look more like Terns’ TERN-701.
